What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, Chowdhury K, Aviles-Olmos I, Limousin P, Foltynie T

Journal of Parkinson's disease1 Jan 2018Cited by 68 (Europe PMC)

PMID29843254DOI10.3233/jpd-181329PepBankPUB-29843254

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, weekly exenatide improved NMSS mood/apathy more than placebo at 48 weeks, but improvement did not persist after withdrawal.
In plain wordsIn Parkinson's disease, exenatide improved mood/apathy scores more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNMSS mood/apathy domain
Study
n: not reported in source
Comparator
placebo
Analysis
Exploratory
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Mood/apathy difference
−3.3 points
versus placebo
Source sentences
Summary
Compared to placebo, patients treated with exenatide-once weekly had greater improvements in individual domains assessing mood/depression across all observer-rated outcome measures after 48 weeks including the "mood/apathy" domain of the NMSS, - 3.3 points (95% CI - 6.2, - 0.4), p = 0.026
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, there was an improvement in the "emotional well-being" domain of the PDQ-39 of 5.7 points ((95% CI - 11.3, - 0.1), p = 0.047 though these improvements were not sustained 12 weeks after exenatide withdrawal.
Summary · context
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Report a problemFND-2984325401
02HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, weekly exenatide improved MDS-UPDRS mood more than placebo at 48 weeks, but improvement did not persist after withdrawal.
In plain wordsIn Parkinson's disease, exenatide improved the MDS-UPDRS mood score more than placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMDS-UPDRS Part 1 mood score
Study
n: not reported in source
Comparator
placebo
Analysis
Exploratory
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Mood score difference
−0.3 points
versus placebo
Source sentences
Summary
the "mood" score (Q1.3+Q1.4 of the MDS-UPDRS Part 1), - 0.3 points (95% CI - 0.6, - 0.1), p = 0.034
2 context sentences(design, population, supporting numbers)
Summary · context
In addition, there was an improvement in the "emotional well-being" domain of the PDQ-39 of 5.7 points ((95% CI - 11.3, - 0.1), p = 0.047 though these improvements were not sustained 12 weeks after exenatide withdrawal.
Summary · context
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Report a problemFND-2984325402
03HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, exenatide showed a nonsignificant trend toward a lower MADRS score than placebo after 48 weeks.
In plain wordsIn Parkinson's disease, exenatide showed a nonsignificant trend toward lower depression scores than placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMADRS total score
Study
n: not reported in source
Comparator
placebo
Analysis
Exploratory
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
MADRS difference
−1.7 points
versus placebo
Source sentences
Summary
and a trend in the MADRS total score, - 1.7 points (95% CI - 3.6, 0.2), p = 0.071.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Report a problemFND-2984325403
04HumanRandomized controlled trialEfficacy outcome
In Parkinson's disease, exenatide improved PDQ-39 emotional well-being by 5.7 points versus placebo, but improvement did not persist after withdrawal.
In plain wordsIn Parkinson's disease, exenatide improved emotional well-being more than placebo, but the improvement did not persist after withdrawal.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePDQ-39 emotional well-being
Study
n: not reported in source
Comparator
placebo
Analysis
Exploratory
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Measurements
Emotional well-being improvement
5.7 points
versus placebo
Source sentences
Summary
In addition, there was an improvement in the "emotional well-being" domain of the PDQ-39 of 5.7 points ((95% CI - 11.3, - 0.1), p = 0.047 though these improvements were not sustained 12 weeks after exenatide withdrawal.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Report a problemFND-2984325404
05HumanRandomized controlled trialOther
In Parkinson's disease, mood changes during exenatide treatment were not associated with changes in motor severity or other factors.
In plain wordsIn Parkinson's disease, mood changes during exenatide treatment were not linked to changes in movement symptoms or other factors.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAssociation of mood changes with motor severity
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 48 weeksAs given in this study (human).
Source sentences
Summary
At 48 weeks these changes were of a magnitude that would be subjectively meaningful to patients and were not associated with changes in motor severity or other factors, suggesting exenatide may exert independent effects on mood dysfunction.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Report a problemFND-2984325405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial page ClinicalTrials.govUpdated 27 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.